Influence of <i>ADORA2A</i> gene polymorphism on leukoencephalopathy risk in MTX‐treated pediatric patients affected by hematological malignancies

Abstract

ADORA2A rs2298383 and high cumulative dose of systemic MTX administration were significantly associated with MTX-related leukoencephalopathy. Our results indicate that pharmacological intervention within the adenosine pathway may be both a treatment and preventative option for MTX-related leukoencephalopathy.